Physician practice platforms often run lean, leaving little to cut after a private equity deal. McGuireWoods partner and host Geoff Cockrell explores where value lies with ECG Management Consultants experts Louis Oster, a principal in its Medical Group Optimization division, and partner Clark Bosslet. 

For Louis, the path forward runs through revenue cycle improvements, provider productivity and organic growth. While Louis favors business-unit phantom equity to keep physicians invested in the performance of their own practices, Clark cautions against cutting physician pay at closing with promises to restore it later. Tune in to learn why steep pay cuts can undermine recruiting and how platforms can balance centralized control with local autonomy.

Consonance Capital Partners (CCP) recently announced it closed its third flagship fund at the hard cap of $1.35 billion.

The firm indicated that the new fund, Consonance Private Equity III, will focus on investments in U.S. healthcare companies in the lower and middle markets, consistent with its previous funds.

CCP, founded in 2005 and based in New York, pursues investments, including growth equity, leveraged buyouts and recapitalization transactions, in U.S. middle market companies exclusively in the healthcare industry. The firm targets companies that generally have between $25 million and $500 million in revenue.

Aphias Capital recently announced the close of its first fund.

The fund, Aphias Capital Fund I, exceeded its $900 million target and closed at just over $1.05 billion in commitments, with investor demand surpassing its hard cap.

Aphias, founded in 2025 and based in San Francisco, is a private equity firm focused on healthcare services and essential services in the lower middle market. The firm generally makes control investments in North American companies with EBITDA of $5 million to $30 million.

A decade ago, co-investment was uncommon. Now it takes up one of every three dollars LPs spend on a fund investment. So how much say should LPs have once the deal closes? Gordon Maner, CEO of AMB group of companies and co-founder of healthcare private equity firm Frontline Healthcare Partners, and his LP Kevin Wong, chief investment officer of Lang Partners, tackle that question from both sides of the table with McGuireWoods partner and host Geoff Cockrell.

Gordon reveals when sector-savvy LPs can earn a bigger co-invest allocation, and Kevin explains what a GP must prove before he’ll double down with a co-investment. Tune in to hear why Gordon never backs a deal that requires co-invest to make it work.

Prairie Capital recently announced its acquisition of Medefil in partnership with executives Ankit Aggarwal and Jack Glerum.

Medefil, founded in 1998 and based in Glendale Heights, Illinois, is a pharmaceutical developer, manufacturer and marketer of prefilled syringe products for acute care end markets.

Prairie, founded in 1997 and based in Chicago, is a private equity firm focusing on the lower middle market. It makes control equity investments in founder-owned companies.

Terms of the transaction were not disclosed.

Avesi Partners recently announced it made an investment in New Age Medical.

New Age, founded in 2012 and based in St. Louis, Missouri, is a medtech hub designed to support the flow of medical solutions, primarily for spinal surgery, from manufacturers, through reps, to hospitals, ambulatory surgery centers and surgeons.

Avesi, founded in 2021 and based in Stamford, Connecticut, is a private equity firm focused on healthcare services, healthcare technology and business services. The firm generally targets lower middle market companies with around $5 million to $30 million of EBITDA.

Terms of the investment were not disclosed.

Webster Equity Partners has entered into a definitive agreement to acquire Lifecore Biomedical in a transaction valued at up to $663.7 million, according to a news release.

Lifecore (Nasdaq: LFCR), founded in 1965 and based in Chaska, Minnesota, is a contract development and manufacturing organization specializing in the development and fill/finish of sterile injectable pharmaceuticals. It is also a manufacturer of injectable-grade hyaluronic acid.

Webster, based in Waltham, Massachusetts, is a middle market private equity firm focused exclusively on healthcare. It typically targets businesses with revenue between $20 million and $200 million. The firm’s identified practice areas are physician practice management, post-acute care, women’s and children’s health, behavioral health and pharma services.

The deal is expected to close at the end of the fourth quarter of 2026. Upon completion, Lifecore’s common stock will be delisted from the Nasdaq stock market

5th Century Partners (5CP) recently announced it made a strategic investment in ION PT Network.

ION, founded in 2017 and based in Tampa, Florida, is a physical therapy management company serving the workers’ compensation market.

5CP, founded in 2020 and based in Chicago, focuses on lower middle market companies within the healthcare and business services industries.

Terms of the investment were not disclosed.

In this episode of the Becker Private Equity & Business Podcast, Holly Buckley, Chair of Healthcare at McGuireWoods, discusses the opportunities and challenges of private equity in healthcare, including regulatory scrutiny, value creation, and alignment among investors, clinicians, and operators.

Value-based care is one of healthcare’s biggest bets on changing how care is delivered and paid for, but how well has it worked? Dawn Owens, CEO and partner at healthcare investor Truehelm, gives the model a “C” overall. 

In this conversation with McGuireWoods partner and host Geoff Cockrell, Dawn explains why this model — in which providers are rewarded for better outcomes and lower costs rather than more services — works better for stable, concentrated populations such as seniors than for commercially insured patients who move between employers and payers. She also discusses why specialist investors are positioned to navigate the sector, how Medicare Advantage disruption is reshaping the market and where AI can ease administrative burdens on primary care physicians.